879399-82-3

Basic information

• Product Name: 4-Thiazoleacetic acid, 2-[[2-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]- 2-oxoethyl]thio]-
• CAS NO: 879399-82-3
• Molecular Formula: C19H21Cl2N3O4S2
• Molecular Weight: 490.431
• Mol File: 879399-82-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-Thiazoleacetic acid, 2-[[2-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]- 2-oxoethyl]thio]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thiazoleacetic acid, 2-[[2-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]- 2-oxoethyl]thio]-(879399-82-3)
• EPA Substance Registry System: 4-Thiazoleacetic acid, 2-[[2-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]- 2-oxoethyl]thio]-(879399-82-3)

Safety Data

• Hazardous Substances Data: 879399-82-3(Hazardous Substances Data)

Upstream product

• 407640-11-3 (2S)-2-aminomethyl-4-(3,4-dichlorobenzyl)morpholine 
• 610305-43-6 2-{[(2R)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-1H-isoindole-1,3-(2H)-dione 
• 879402-33-2 (2S)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(ethoxycarbonylmethyl)thiazol-2-ylthio]acetamide 
• 879402-30-9 (2S)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}chloroacetamide 
• 38449-49-9 2-mercapto-thiazole-4-acetic acid,ethyl ester 

Downstream Products

• 1002092-13-8 (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide potassium salt 
• 1002092-12-7 (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide hydrobromide 

Relevant articles and documents

THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE

The present invention provides a therapeutic agent or prophylactic agent for an ophthalmic disease caused by ocular angiogenesis, which contains a morpholine compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) a

MORPHOLINE COMPOUND

A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.